> News > Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Lausanne, Switzerland, February 17, 2021 – (PR Newswire) - Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
The undisclosed amounts of the equity investment in three instalments, allow Onward to become the majority shareholder. Dr. Alain Herrera, Chief Medical Officer of Onward, has been elected Chairperson of the Board of EMERCell.
In the era of cancer immunotherapy, NK cells are one of the immune cells that can be harnessed, along with antibodies or genetic modifications to kill tumor cells. One major advantage of EMERCell’s
technology is its versatility in offering allogeneic, instead of autologous treatment by CAR-T or CAR-NK cell therapy. Onward will assist EMERCell to scale up their patented process of activation and
amplification of allogeneic NK cells and to conduct clinical investigations.